AACR: Bay Area biotech bets on antibodies armed with immuno-stimulant to fight checkpoint-resistant cancers
The scientist behind the first prostate cancer vaccine Provenge — once celebrated as a historic breakthrough, but now a fading star — has devised a type of armed antibody — loaded with an immuno-stimulant rather than a cytotoxic payload — to fight cancers resistant to the army of existing checkpoint inhibitors.
The researcher, Stanford’s Ed Engleman, has built on his research into dendritic cells — which are considered ‘sentinels’ of the immune system as they are responsible for inducing immune T-cell responses — to develop this Immune-Stimulating Antibody Conjugate (ISAC) technology, which was unveiled by exclusive licensee Bolt Biotherapeutics at the American Association for Cancer Research (AACR) Conference on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
